Collectively, our data have demonstrated the function of MYSM1 on maintenance of ERα stability and modulation of ERα action to confer antiestrogen insensitivity in ERα-positive breast cancer, providing a potential therapeutic target for endocrine resistance in ERα-positive BCa. This evidence concerns the gene MYSM1 and breast cancer.